MBX BiosciencesMBX +4.07%12 Quick Ratio is 30.79 as of Mar. 2026, which is 30% above its 10-year median of 23.75. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, MBX Biosciences ranks better than 96.75% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. MBX Biosciences's quick ratio for the quarter that ended in Mar. 2026 was 30.79.
MBX Biosciences has a quick ratio of 30.79. It generally indicates good short-term financial strength.
The historical rank and industry rank for MBX Biosciences's Quick Ratio or its related term are showing as below:
MBX'
s Quick Ratio Range Over the Past 10 Years
Min: 7.17 Med: 23.75 Max: 32.95
Current: 30.79
During the past 4 years, MBX Biosciences's highest Quick Ratio was 32.95. The lowest was 7.17. And the median was 23.75.
MBX's Quick Ratio is ranked better than 96.75% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs MBX: 30.79
MBX Biosciences (NAS:MBX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
MBX Biosciences Quick Ratio Related Terms
MBX Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for MBX Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MBX Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MBX Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MBX Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where MBX Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
MBX Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBX Biosciences (MBX) has a Quick Ratio of 30.79 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MBX Biosciences and its competitors. This is 30% above median its historical median of 23.75. Over the past decade, MBX Biosciences' Quick Ratio has ranged from 7.17 to 32.95. According to the industry distribution chart, MBX Biosciences ranks #46 out of 1416 companies in the Biotechnology industry, placing it in the top 3.2%.
Is MBX Biosciences' Quick Ratio too high?
MBX Biosciences' current Quick Ratio of 30.79 is 30% above median its 10-year median of 23.75. Over the past 10 years, this metric has ranged from a low of 7.17 to a high of 32.95. The Biotechnology industry median Quick Ratio is 3.60. MBX Biosciences' value of 30.79 is 755.3% above this industry median. Based on the distribution chart, MBX Biosciences ranks #46 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Quick Ratio compare to ARDX and INBX?
According to the Biotechnology industry distribution chart, MBX Biosciences ranks #46 out of 1416 companies for Quick Ratio. This places MBX Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. MBX Biosciences' value of 30.79 is 755.3% above this benchmark. Historically, MBX Biosciences' own Quick Ratio has ranged from 7.17 to 32.95 over the past decade. While the company's 10-year median is 23.75 vs. the industry median of 3.60, MBX Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MBX Biosciences's current Quick Ratio of 30.79 is 755.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on MBX Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MBX Biosciences's current Quick Ratio is 30.79, which is 30% above median its own 10-year median of 23.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Quick Ratio of 30.79. The current Quick Ratio is 30.79, which is 30% above median its 10-year median of 23.75 and 755.3% above the Biotechnology industry median of 3.60. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Quick Ratio is 30.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score
Get the complete analysis for MBX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBX has been successfully added to your 
